John Duncan Higgons
Chairman at Akamis Bio Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Cary Pfeffer | M | 61 |
Rheos Medicines, Inc.
 Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | 11 years |
| David Schenkein | M | 66 | 15 years | |
| Abbie Celniker | M | 65 |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | - |
| Eric Laub | M | - | 3 years | |
| Howard Davis | M | - |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | 2 years |
| Jacquelyn Sandell | F | - | 5 years | |
| Kaye Foster-Cheek | F | 64 | 10 years | |
| Paolo Augusto Paoletti | M | 73 |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | 9 years |
| May Kin Ho | M | 71 | 9 years | |
| Samuel Cameron Williams | M | 55 |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Matthew Foy | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Mette Agger | F | 59 |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Barbara Fox | M | - |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | 5 years |
| Brian Champion | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Jim Burns | M | 46 | 8 years | |
| Allison Nance | F | - | 8 years | |
| John C. Davis | M | 62 |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | 3 years |
| Ezra Cohen | M | - |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | - |
| Nirupama Subramanian | F | - |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | 3 years |
| Stephen Sherwin | M | 75 |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Perry Karsen | M | 69 | 12 years | |
| Kevin Starr | M | 61 | 7 years | |
| John Maraganore | M | 60 | 13 years | |
| Jigar Raythatha | M | 47 | 8 years | |
| Marc Tessier-Lavigne | M | 64 | 5 years | |
| Luis Diaz | M | 53 | 6 years | |
| Min Wang | M | - | 8 years | |
| Laurence Turka | M | 66 |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | 2 years |
| Hugh Cole | M | 59 | 6 years | |
| Anna L. Barry | M | - | 5 years | |
| Barbara Duncan | F | 59 | 7 years | |
| Darrin Miles | M | - | 6 years | |
| Glenn Goddard | M | 53 | 6 years | |
| Robert Iannone | M | 57 | 3 years | |
| Malin Deon | F | - | - | |
| Paul Clancy | M | 62 | 10 years | |
| Chuck Wilson | M | 59 |
Archemix Corp.
 Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | 7 years |
| Megan E. Pace | F | 51 | - | |
| Jacqueline Cinicola | F | - | 7 years | |
| Sanjay Keswani | M | 54 |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | 1 years |
| Eyal Attar | M | 53 | 5 years | |
| Luisa Salter-Cid | M | 60 | 2 years | |
| Samuel Agresta | M | 51 | 7 years | |
| Emma Lees | M | - | 1 years | |
| Ann J. Barbier | M | 59 | 2 years | |
| Dmitri Wiederschain | M | - | - | |
| Richa Poddar | F | - | 6 years | |
| Haley Laken | M | - | - | |
| Jennifer Michaelson | M | 57 | 5 years | |
| Robert Sheroff | M | 69 | 2 years | |
| Renee T. Leck | F | - | 3 years | |
| Melissa McLaughlin | F | - | 7 years | |
| Camille Henderson | M | - | 4 years | |
| Scott Biller | M | 68 | 9 years | |
| Christopher Bowden | M | 63 | 7 years | |
| Marion Dorsch | M | 59 | 4 years | |
| Robert J. DeVita | M | - | - | |
| John Evans | M | 46 | 8 years | |
| Elizabeth G. Trehu | M | 64 | 8 years | |
| Mark Angelino | M | 51 |
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | 2 years |
| James C. Gilbert | M | - |
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | - |
| Deborah Law | M | - | 3 years | |
| Gregg Beloff | M | 56 |
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | 6 years |
| Robert Stein | M | 73 |
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | - |
| Ramani Varanasi | F | 54 |
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | 1 years |
| Meredith Goldwasser | M | 52 | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 59 | 89.39% |
| United Kingdom | 7 | 10.61% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Duncan Higgons
- Personal Network
